TruSight Oncology 500 ctDNA
(TSO500 ctDNA)

Minimally invasive, pan-cancer next-generation sequencing assay for biomarker identification and comprehensive genomic profiling across 523 genes

A Hybrid-Capture Approach for Target Enrichment of 523 Genes Across Various Tumor Types​


Gain an expansive view of your liquid biopsy samples by targeting 523 cancer-related genes using the TruSight Oncology 500 ctDNA assay. Not only does this assay identify all relevant variants (DNA fusions, SNVs, CNVs, insertions, and deletions) across various tumor types, but it also reports tumor mutational burden (TMB) and microsatellite instability (MSI) scores.


Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 Solutions can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.


An Efficient, Reliable Solution for Non-Invasive Tumor Characterization

minimal-sample-redMinimal input, extensive results
Obtain full exon coverage of 522 out of 523 genes using as little as 3 mL of plasma, 20-30 ng of cfDNA, or 10 mL of whole blood. TSO500 ctDNA can detect biomarkers without the need of a matched normal sample.

workflow-savings-redSimple, cost-effective workflow
Detect multiple biomarkers with a single assay to save time, money, and samples. The distributable kit enables global implementation.

precision-redConfident variant detection
Obtain a high-resolution view of variants enabled by TSO500 ctDNA’s hybrid-capture chemistry and unique molecular indices (UMIs).​

measure-dna-redMeasurement of key immuno-oncology biomarkers
Gain insight into TMB score and MSI score in addition to variant calls. TruSight Oncology 500 ctDNA can reproducibly assess TMB.

global-network-redExpansive services enabled by our global network
Our centralized, scientific operational oversight combined with our global laboratory footprint enable comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.

flexible-filter-redFlexible customization to satisfy specific needs
We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.

TSO500 ctDNA Variant Detection

TSO500 ctDNA Variant Detection

TSO500 Assay Comparison





Request a Quote

Deep Sequencing Enabled by Q2 Solutions’ Subject Matter Expertise

Feel confident in your results with the trusted Illumina® software pipeline. Our software teams validate the most up-to-date software to ensure you are receiving optimal results. Q2 Solutions can develop custom reporting and filtering to meet your specific research needs. Q2 Solutions was one of the earliest adopters of DRAGEN™. Our technical support teams help you understand your deep sequencing data with our superior bioinformatics knowledge.

Close up of blue Printed Circuit Board


Q2 Solutions provides a text-delimited, combined variant output file for all biomarkers

  • QC Metrics​
  • CNV Outputs​
  • DNA Fusion Report​
  • Genomic VCFs (SNVs & Indels)​
  • Variant Call Annotations
  • MSI Scores​
  • TMB Scores​
  • FASTQs Upon Request​
  • BAMs Upon Request

Supporting Studies Around the World

Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.




Learn More About TSO500 with Q2 Solutions

Simplify Your Work



Request a Quote

Request a quote today to discover how TSO500 with Q2 Solutions can advance your research.

Ship Samples

Ship your samples to one of our global genomic laboratory centers.​

Get Results

Obtain in-depth data revealing insights into your solid tumor samples.

Request a Quote

Related Thought Leaders Insights

Non-invasive Detection of Immunotherapy Biomarkers using TruSight Oncology 500 (TSO500)

The TruSight Oncology 500 (TSO500) ctDNA assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable ultra-low frequency...

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma.Two approaches of specific interest due to the innovation they...

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

Author: Victor Weigman, Ph.D., Associate Director, Associate Director, Translational Genomics, Q2 SolutionsThe excitement surrounding immuno-oncology (I-O) is being driven by results seen in the...